Skip to main content
. 2010 May 10;28(18):2966–2973. doi: 10.1200/JCO.2009.25.9549

Fig 3.

Fig 3.

Disease-free survival (DFS) and overall survival (OS) comparing patients assigned to CMF (cyclophosphamide, methotrexate, and fluorouracil) chemotherapy with patients assigned to no CMF chemotherapy with triple-negative (A,D), human epidermal growth factor receptor 2 (HER2) –positive, endocrine receptor–absent (B,E), and endocrine receptor–present (C,F) subtypes. Pts, patients; yr, year.